Efficacy and Safety of PR022 Topical Gel to Treat Mild-to-Moderate Atopic Dermatitis

Trial Profile

Efficacy and Safety of PR022 Topical Gel to Treat Mild-to-Moderate Atopic Dermatitis

Recruiting
Phase of Trial: Phase II

Latest Information Update: 15 Feb 2018

At a glance

  • Drugs Hypochlorous acid (Primary)
  • Indications Atopic dermatitis
  • Focus Therapeutic Use
  • Sponsors Realm Therapeutics
  • Most Recent Events

    • 15 Feb 2018 According to Realm Therapeutics media release, the study is progressing as planned and top-line results are expected by the end of Q3.
    • 19 Dec 2017 Status changed from not yet recruiting to recruiting.
    • 16 Oct 2017 According to Realm Therapeutics media release, the Company remains on track to initiate this trial by end of the year 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top